

OncoCyte Corp  
Form 8-K  
October 23, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): **October 17, 2018**

**OncoCyte Corporation**

(Exact name of registrant as specified in its charter)

**California**                      **1-37648**      **27-1041563**  
(State or other jurisdiction (Commission (IRS Employer  
of incorporation)              File Number) Identification No.)

**1010 Atlantic Avenue**

**Suite 102**

**Alameda, California 94501**

(Address of principal executive offices)

**(510) 775-0515**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## **Forward-Looking Statements**

*Any statements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,” “believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in OncoCyte Corporation’s Form 10 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and other filings that OncoCyte may make with the SEC. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, OncoCyte disclaims any intent or obligation to update these forward-looking statements.*

References to “OncoCyte,” “we” or “us” are references to OncoCyte Corporation

## **Section 5 - Corporate Governance and Management**

### **Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

#### *Executive Compensation*

On October 17, 2018, we granted stock options to purchase 54,000 shares of our common stock to Lyndal Hesterberg, Senior Vice President Research & Development. The stock options were granted under our 2018 Equity Incentive Plan (the “Plan”). The exercise price of such options is \$1.95, the fair market value of OncoCyte common stock determined in accordance with the Plan.

The options shall vest and thereby become exercisable in three equal annual installments from the date of grant, such that the first installment shall vest on the first anniversary date of the grant, with vesting of each installment conditioned upon the executive’s continuous service as an OncoCyte employee on the applicable vesting date.

The options shall expire if not exercised 10 years from the date of grant. However, in the event of termination of the executive’s continuous service as an employee for any reason other than death or disability, the options will expire three months following the termination of employment, and in the event of the executive’s death or disability, the

options will expire if not exercised within the first year following cessation of continuous service as an employee due to death or disability, and in each case may be exercisable only up to the amount vested on the date of death or disability.

The options shall be incentive stock options pursuant to Section 422 of the Internal Revenue Code, to the extent permitted by the Code.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ONCOCYTE CORPORATION**

Date: October 22, 2018 By: */s/ William Annett*  
William Annett  
President and Chief Executive Officer

